137 related articles for article (PubMed ID: 38738708)
21. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity.
Wei B; Gunzner-Toste J; Yao H; Wang T; Wang J; Xu Z; Chen J; Wai J; Nonomiya J; Tsai SP; Chuh J; Kozak KR; Liu Y; Yu SF; Lau J; Li G; Phillips GD; Leipold D; Kamath A; Su D; Xu K; Eigenbrot C; Steinbacher S; Ohri R; Raab H; Staben LR; Zhao G; Flygare JA; Pillow TH; Verma V; Masterson LA; Howard PW; Safina B
J Med Chem; 2018 Feb; 61(3):989-1000. PubMed ID: 29227683
[TBL] [Abstract][Full Text] [Related]
23. Quantitative Conjugated Payload Measurement Using Enzymatic Release of Antibody-Drug Conjugate with Cleavable Linker.
Rago B; Tumey LN; Wei C; Barletta F; Clark T; Hansel S; Han X
Bioconjug Chem; 2017 Feb; 28(2):620-626. PubMed ID: 28140559
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
25. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
26. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
27. Effect of attachment site on stability of cleavable antibody drug conjugates.
Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
[TBL] [Abstract][Full Text] [Related]
28. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P
Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918
[TBL] [Abstract][Full Text] [Related]
29. Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates.
Tedeschini T; Campara B; Grigoletto A; Bellini M; Salvalaio M; Matsuno Y; Suzuki A; Yoshioka H; Pasut G
J Control Release; 2021 Sep; 337():431-447. PubMed ID: 34329685
[TBL] [Abstract][Full Text] [Related]
30. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D
Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822
[TBL] [Abstract][Full Text] [Related]
31. Method development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker drug analyte.
Hyung SJ; Li D; Koppada N; Kaur S; Saad OM
Anal Bioanal Chem; 2019 May; 411(12):2587-2596. PubMed ID: 30828756
[TBL] [Abstract][Full Text] [Related]
32. Optimizing the enzymatic release of MMAE from
Zambra M; Ranđelović I; Talarico F; Borbély A; Svajda L; Tóvári J; Mező G; Bodero L; Colombo S; Arrigoni F; Fasola E; Gazzola S; Piarulli U
Front Pharmacol; 2023; 14():1215694. PubMed ID: 37492088
[TBL] [Abstract][Full Text] [Related]
33. Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.
Dal Corso A; Cazzamalli S; Gébleux R; Mattarella M; Neri D
Bioconjug Chem; 2017 Jul; 28(7):1826-1833. PubMed ID: 28662334
[TBL] [Abstract][Full Text] [Related]
34. On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency.
Dovgan I; Ehkirch A; Lehot V; Kuhn I; Koniev O; Kolodych S; Hentz A; Ripoll M; Ursuegui S; Nothisen M; Cianférani S; Wagner A
Sci Rep; 2020 May; 10(1):7691. PubMed ID: 32376903
[TBL] [Abstract][Full Text] [Related]
35. A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate.
Xiao D; Zhao L; Xie F; Fan S; Liu L; Li W; Cao R; Li S; Zhong W; Zhou X
Theranostics; 2021; 11(6):2550-2563. PubMed ID: 33456559
[TBL] [Abstract][Full Text] [Related]
36. Cathepsin B Processing Is Required for the
Bernardim B; Conde J; Hakala T; Becher JB; Canzano M; Vasco AV; Knowles TPJ; Cameron J; Bernardes GJL
Bioconjug Chem; 2024 Feb; 35(2):132-139. PubMed ID: 38345213
[TBL] [Abstract][Full Text] [Related]
37. Late-Stage Desulfurization Enables Rapid and Efficient Solid-Phase Synthesis of Cathepsin-Cleavable Linkers for Antibody-Drug Conjugates.
Ahangarpour M; Brimble MA; Kavianinia I
Bioconjug Chem; 2024 Jun; ():. PubMed ID: 38874557
[TBL] [Abstract][Full Text] [Related]
38. Conjugation Site Influences Antibody-Conjugated Drug PK Assays: Case Studies for Disulfide-Linked, Self-Immolating Next-Generation Antibody Drug Conjugates.
Lee MV; Kaur S; Saad OM
Anal Chem; 2020 Sep; 92(18):12168-12175. PubMed ID: 32786429
[TBL] [Abstract][Full Text] [Related]
39. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker.
Liubomirski Y; Tiram G; Scomparin A; Gnaim S; Das S; Gholap S; Ge L; Yeini E; Shelef O; Zauberman A; Berger N; Kalimi D; Toister-Achituv M; Schröter C; Dickgiesser S; Tonillo J; Shan M; Deutsch C; Sweeney-Lasch S; Shabat D; Satchi-Fainaro R
J Control Release; 2024 Mar; 367():148-157. PubMed ID: 38228272
[TBL] [Abstract][Full Text] [Related]
40. A Bispecific METxMET Antibody-Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes.
Perez Bay AE; Faulkner D; DaSilva JO; Young TM; Yang K; Giurleo JT; Ma D; Delfino FJ; Olson WC; Thurston G; Daly C; Andreev J
Mol Cancer Ther; 2023 Mar; 22(3):357-370. PubMed ID: 36861363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
